| Revenue Growth | License revenue up 39%; EMEA revenue grew 39% with license fees doubling. |
|---|---|
| Mgmt Confidence | Highly encouraged; targeting consistent profitability and positive cash flow by 2027. |
| Demand Visibility | Pipeline includes seven-figure opportunities; eight new Middle East customers in seven months. |
| Margin Trends | Gross margin improved sequentially to 90% from 77% a year ago. |
| Op. Leverage | Operating loss reduced 8% as high-margin software offsets lower hardware sales. |
| Pricing Power | Charging more for lower quantity hardware units; three-year prepaid casino contract. |
| Vol vs Price | Growth driven by license volume and shift to recurring software fees. |
| Segment Growth | Software license revenue is 86% of total; hardware revenue fell to $12k. |
| New Clients | Central Bank of Jordan, Portugal National Security, and major U.S. casino. |
| Capex & Debt | Retired remaining debt; effectively debt-free with $2.2M cash and $2.4M receivables. |
| Regulatory | UAE Central Bank phasing out SMS OTPs creates biometric tailwinds. |
| Commentary | Focusing on 'Identity Bound Biometrics' to secure rogue AI agents. |
| New Launches | Launched PortalGuard 7, Passkey Authenticator, and Saudi Arabian subsidiary establishment. |
Growth
License revenue grew 39% year-over-year; total nine-month revenue rose 14% to $5.5M.
Outlook
Targeting profitability in Q1 2027 with $1.2M in expected license renewals.
Risks
Management pivoted on hardware slippage, citing 'dribbling' orders and civil ID program delays.
The company's earnings call, NASDAQ: BKYI, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Bio Key International Inc: key numbers
- Share price
- $2.09Close, Nov 16
- Market cap
- $4.25M
- Shares outstanding
- 2.04MLatest SEC cover page
- Sector
- Technology
- Industry
- Services-Prepackaged SoftwareSIC 7372
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Bio Key International Inc
All →Bio Key International Q3 2026 Results: Net Loss of $886K, Loss Narrows
BIO-key International reported total revenues of $5.5M for the nine months ended September 30, 2026, an increase from $4.9M in the prior year period, driven by higher license fees. Despite the revenue growth, the company incurred a net loss available to common stockholders of $6.2M, significantly impacted by a $4.5M deemed dividend related to a warrant inducement.
- Key figure
- Net loss $886K
Bio Key International Financial Results
BIO-key International reported Q3 2026 financial results, highlighted by a 39% increase in software license fee revenue to $1.3 million and a gross margin improvement to 90%. The company narrowed its quarterly net loss to $0.89 million and retired its remaining outstanding debt, leaving the firm effectively debt-free.
- Term
- Q3 2026
“Our Q3’26 results reflect the building strength of our core software business. Software license fee revenue grew 39% in Q3’26, offsetting variability in our more episodic hardware and services revenue and lifting gross margin to 90% from 77% a year ago.”
Mike DePasquale, CEO
“Year to date we have grown revenue by 14%, reduced our net loss by 42% and we retired our remaining note outstanding leaving us effectively debt free.”
Mike DePasquale, CEO
Bio Key International Shareholder Meeting
BIO-key International reported the final voting results from its 2026 Annual Meeting of Stockholders, which concluded on October 30, 2026. Stockholders approved Proposal 4, authorizing the issuance of up to 1,236,668 shares of common stock upon the exercise of warrants from an August 2026 inducement transaction to comply with Nasdaq Listing Rule 5635(d).
Bio Key International Shareholder Meeting
BIO-key International held its reconvened 2026 Annual Meeting of Stockholders on October 2, 2026, where shareholders elected five directors, ratified M&K CPAs, PLLC as auditors, and approved executive compensation on an advisory basis. The meeting was further adjourned until October 30, 2026, to allow more time for stockholders to vote on Proposal 4 regarding the issuance of common stock upon the exercise of warrants.
Bio Key International Debt Financing Update with Streeterville Capital, LLC
BIO-key International entered into exchange agreements with Streeterville Capital to settle the remaining $416,315.80 balance of a 2025 secured promissory note. The company partitioned the debt into four new notes and immediately exchanged them for 247,805 shares of common stock. As a result of these transactions, the original note has been paid in full.
- Counterparty
- Streeterville Capital, LLC